Research programme: mesenchymal stem cell-derived secretory factors - Sentien Biotechnologies

Drug Profile

Research programme: mesenchymal stem cell-derived secretory factors - Sentien Biotechnologies

Alternative Names: Extracorporeal stem cell therapy - Sentien Biotechnologies; MSC-derived secretions; Sentinel; Stem cell therapeutics device - Sentien Biotechnologies

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Sentien Biotechnologies
  • Class Stem cell factors
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute kidney injury
  • No development reported Adult respiratory distress syndrome; Graft-versus-host disease; Liver disorders; Myocardial infarction; Pancreatitis; Renal failure

Most Recent Events

  • 02 Nov 2016 Mesenchymal stem cell-derived secretory factor is still in preclinical development for Acute kidney injury in USA
  • 02 Nov 2016 Sentien Biotechnologies intends to file an IND application with the US FDA for Acute Kidney Injury
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top